Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review
Prenatal Diagnosis · 2023
DOI: 10.1002/pd.6459 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Prenatal Diagnosis, 2023. Verfasst von Rachel L Sagar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK. Hauptthemen laut MEDLINE: Pregnancy Outcome, Prenatal Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EIT Health.
Abstract (Originalsprache)
Objective
To investigate the maternal and fetal safety of In utero stem cell transplantation (IUSCT).
Methods
Medline®, Embase and Cochrane library (1967−2023) search for publications reporting IUSCT in humans. Two reviewers independently screened abstracts and full‐text papers.
Results
Sixty six transplantation procedures in 52 fetuses were performed for haemoglobinopathies ( n = 14), red cell/bleeding disorders ( n = 4), immunodeficiencies ( n = 15), storage disorders ( n = 7), osteogenesis imperfecta ( n = 2) and healthy fetuses ( n = 10). The average gestational age was 18.9 weeks; of procedures reporting the injection route, cells were delivered by intraperitoneal ( n = 37), intravenous ( n = 19), or intracardiac ( n = 4) injection or a combination ( n = 3); most fetuses received one injection ( n = 41). Haematopoietic ( n = 40) or mesenchymal ( n = 12) stem cells were delivered. The cell dose was inconsistently reported (range 1.8−3.3 × 10 9 cells total ( n = 27); 2.7−5.0 × 10 9 /kg estimated fetal weight ( n = 17)). The acute fetal procedural complication rate was 4.5% (3/66); the acute fetal mortality rate was 3.0% (2/66). Neonatal survival was 69.2% (36/52). Immediate maternal and pregnancy outcomes were reported in only 30.8% (16/52) and 44.2% (23/52) of cases respectively. Four fetal/pregnancy outcomes would also classify as ≥ Grade 2 maternal adverse events.
Conclusions
Short‐, medium‐, and long‐term maternal and fetal adverse events should be reported in all IUSCT studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.
- Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska Institutet, ANA Futura, Huddinge, Sweden.
- NIHR University College London Hospitals Biomedical Research Centre, London, UK.
ORCID-Profile: Anna L David
Förderung
- EIT Health
Zitieren
APA
Sagar, R. L., Walther-Jallow, L., Götherström, C., Westgren, M., & David, A. L. (2023). Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review. Prenatal Diagnosis. https://doi.org/10.1002/pd.6459
Vancouver
Sagar RL, Walther-Jallow L, Götherström C, Westgren M, David AL. Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review. Prenatal Diagnosis. 2023. doi:10.1002/pd.6459
BibTeX
@article{Sagar2023,
author = {Sagar, Rachel L and Walther-Jallow, Lilian and Götherström, Cecilia and Westgren, Magnus and David, Anna L},
title = {Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review},
journal = {Prenatal Diagnosis},
year = {2023},
doi = {10.1002/pd.6459}
}
EUVIMED